GeneralNeutralBlockonomi · 6h ago5/10
📰
AbbVie (ABBV) Stock Dips as $10.9B Apogee Therapeutics Acquisition Nears Completion
AbbVie's stock declined 2% as its $10.9 billion acquisition of Apogee Therapeutics moves toward completion. JPMorgan analysts view the deal as strategically sound, citing significant expansion of AbbVie's immunology pipeline and long-term value creation potential despite near-term market weakness.